REGULATORY
GSK/Vir’s COVID-19 Drug Up for MHLW Panel Review on Sept. 27
September 22, 2021
GlaxoSmithKline’s COVID-19 antibody treatment sotrovimab will come up for review by a key health ministry panel on September 27. If a previous coronavirus drug is a guide, it could land special emergency approval in Japan…

LATEST

September 21, 2021
Competition in the chronic heart failure drug market is heating up with Bayer Yakuhin becoming the latest to join the fray. The company rolled out Verquvo (vericiguat) on September 15, pitting it against three contenders launched over the past few…
September 21, 2021
The ruling Liberal Democratic Party’s (LDP) presidential race kicked off on September 17, with four candidates vying for the top seat that effectively means Japan’s premiership. All four have pledged to boost social security policies,…
September 21, 2021
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) is conducting a questionnaire survey on drug makers’ efforts for stable supplies of ethical drugs at the request of the health ministry. This survey will investigate the current supply status of…
By Ludwig Kanzler

As reported previously, Reed Maurer passed away on August 30 due to complications from pneumonia. He was approaching his 84th birthday.Reed has been a driver of the international pharma community in Japan like nobody else. Arriving over fifty years ago…

By Takashi Ohama

Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA